Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryotherapy vs salicylic acid vs expectant management for common warts in general practice
NL-OMON26788Not yet recruiting
- Sponsor
- ZonMw Fonds Alledaagse Ziekten
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Salvax in common wart (3 arms), sponsored by ZonMw Fonds Alledaagse Ziekten. Primary endpoint: Primary cure rate at 13 weeks. Planned start Mar 2006; status: not yet recruiting.
02
Drugs
Salvax
03
Conditions
common wart
Beyond the preview
Go deeper on NL-OMON26788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26788.